
Myriad Genetics Data Breach Exposes Sensitive Patient Information - Claim Depot
Myriad Genetics Inc., a biotechnology company specializing in genetic testing, has disclosed a data breach to the U.S. Securities and Exchange Commission on Nov. 2, 2026.
As a molecular diagnostic testing company, Myriad Genetics works directly with patients, healthcare providers and medical institutions across the country. Through its regular business operations, the company collects and processes personal and health-related information from individuals who use its testing and precision medicine services.
Limited Details Available
At this time, the specific details of the breach remain limited in the available public disclosures. Information about how the breach occurred, including the method of attack and the timeline of unauthorized activity, has not been detailed. The categories of personal data that were exposed and the total number of individuals affected remain publicly undisclosed.
Company Response
Consumers who have used Myriad Genetics' genetic testing services should monitor their mail and email closely for any official communications from the company in the coming weeks and months. Any notification letter or email from Myriad Genetics may include important details about the nature of the breach, the specific types of personal or health information that were involved and what resources, services or next steps are available to those who were impacted.